R7E.F Cybin Inc.
- Market cap
- EUR 795M
- P/E
- -
- P/B
- 2.67x
- ROE
- -79.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is R7E.F undervalued?
Graham numberThe Graham number of Cybin Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cybin Inc. fundamental analysis
No fundamental analysis for Cybin Inc. yet.
Cybin Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cybin Inc.
Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product inc…
Full company profileCybin Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cybin Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | - | - | - | - | - |
| Operating Income | -63.8M | -51.5M | -78.8M | -103M | -143M | -196M |
| EBITDA | - | -51.3M | -78.4M | -103M | -142M | -196M |
| Net Income | -67.6M | -47.5M | -78.1M | -81.6M | -148M | -191M |
| EPS | -16 | -9.21 | -3.90 | -3.78 | -2.86 | -3.09 |
| Balance Sheet | ||||||
| Total Assets | 84.1M | 53.9M | 302M | 259M | 251M | 260M |
| Total Liabilities | 7.91M | 5.66M | 10.1M | 21.4M | 19.4M | 17.6M |
| Shareholders' Equity | 76.2M | 48.2M | 292M | 237M | 232M | 242M |
| Cash & Short-term Investments | 53.6M | 16.6M | 209M | 135M | 157M | 166M |
| Cash Flow | ||||||
| Operating Cash Flow | -45.2M | -47.4M | -68.9M | -72.3M | -133M | -148M |
| Capital Expenditure | 520K | 3.31M | 710K | 1.40M | 1.37M | 1.28M |
| Free Cash Flow | -45.7M | -50.7M | -69.6M | -73.7M | -135M | -150M |
| Ratios | ||||||
| ROE | -88.8% | -98.5% | -26.7% | -34.4% | -63.9% | -79.0% |
| ROA | -80.5% | -88.1% | -25.9% | -31.6% | -58.9% | -73.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Cybin Inc. dividends
Cybin Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:38 on Sep 19, 2024.
Who owns Cybin Inc.
- Insiders 12.89%
- Institutions 41.10%
- Public & others 46.01%
- Shares outstanding 73.1M
- Free float 58.0M
Cybin Inc. company profile
- Company name
- Cybin Inc.
- Ticker
- R7E.F
- ISIN
- CA23256X4075
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Fiscal year end
- March
- Address
- 100 King Street West, Toronto, ON, Canada, M5X 1C9
- Phone
- 908 764 8385
- Website
- helus.com
About Cybin Inc.
Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. The company was founded in 2019 and is headquartered in Toronto, Canada.
Cybin Inc. management
10- Mr. Eric So L.L.B.Co-Founder, President & Executive Chairman · born 1976
- Mr. Paul GlavineCo-Founder, Chief Growth Officer & Director · born 1989
- Mr. Greg CaversChief Financial Officer · born 1971
- Mr. Aaron BartloneChief Operating Officer · born 1967
- Dr. Amir Inamdar FFPM, MBBSChief Medical Officer · born 1974
- Mr. Michael I. Halstead J.D.CEO & Director · born 1973
- Mr. John KanakisCo-Founder · born 1980
- Dr. Alex L. Nivorozhkin Ph.D.Chief Scientific Officer · born 1960
- Ms. Lori ChallengerChief Compliance, Ethics & Administrative Officer
- Mr. Gabriel FahelChief Legal Officer & Corporate Secretary · born 1976